Express News | Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data From Phase 2 Trial in Second-Line Kras Mutant Mcrc
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $8
Craig-Hallum analyst Albert Lowe maintains $Cardiff Oncology(CRDF.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 40.0% and
Cardiff Oncology Analyst Ratings
Craig-Hallum Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $8
Craig-Hallum analyst Albert Lowe initiates coverage on $Cardiff Oncology(CRDF.US)$ with a buy rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate of 77.8
Express News | Cardiff Oncology : Craig-Hallum Initiates Coverage With Buy Rating and Target Price $8
Earnings Call: Cardiff Oncology Q2 2024 Update on CRDF-004 Trial and Finances